Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000658492 | SCV000780260 | uncertain significance | not provided | 2017-12-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000707644 | SCV000836746 | uncertain significance | Charcot-Marie-Tooth disease, type 2 | 2018-05-16 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with glycine at codon 100 of the MFN2 protein (p.Ala100Gly). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and glycine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with Charcot–Marie–Tooth disease (PMID: 16714318, 22492563). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). The observation of one or more missense substitutions at this codon (p.Ala100Phe) in affected individuals suggests that this may be a clinically significant residue (PMID: 26989944). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Inherited Neuropathy Consortium | RCV000790051 | SCV000929441 | uncertain significance | Charcot-Marie-Tooth disease | no assertion criteria provided | literature only |